Description |
Oxyfedrine, a vasodilator, is an orally active β-adrenoreceptor agonist. Oxyfedrine decreases the tonicity of coronary vessels. Oxyfedrine can be used in the research of cardiovascular disease[1][2].
|
Related Catalog |
|
Target |
β-adrenoceptor
|
In Vitro |
Oxyfedrine (50 μM, 48 h) suppresses aldehyde dehydrogenase (ALDH) activity in HCT116 and HSC-4 cells[1]. Oxyfedrine (50 μM, 48 h) acts as a sensitizer for GSH-depleting agents, and induces cell death in HCT116 and HSC-4 cells when with the drug combinations[1]. Oxyfedrine (0-1 μg/mL) inhibits spontaneous myogenic activity in rat isolated portal vein[4].
|
In Vivo |
Oxyfedrine (14 mg/kg, p.o., for 3-4 weeks) shows anti-anginal action in cats[2]. Oxyfedrine (10 mg/kg, i.p., HCT116 cell xenograft mice) suppresses tumor growth when combined with sulfasalazine (SSZ, 350 mg/kg, i.p.)[1]. Oxyfedrine (1 mg/kg, i.v.) decreases the arterial and venous blood high blood viscosity (HBV) in ice water stress rats[3]. Animal Model: Cats[2] Dosage: 14 mg/kg Administration: Oral administration (p.o.), for 3-4 weeks. Result: Decreased systolic and diastolic blood pressures, increased heart rate and cardiac output.
|